Quick Dispatch:
Your pharma news today obesity drugs glp-1 october 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your pharma news today obesity drugs glp-1 october 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.) ships.
Need Help?
Questions about pharma news today obesity drugs glp-1 october 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for pharma news today obesity drugs glp-1 october 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.) in your area.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity November 5, 2025 DOI: 10.1056/NEJMdo008238 New for the treatment of obesity - and so many additional indications being studied
24.12
What is the pipeline for future medications for obesity?
20.19
Patient Behavior: How Does Price Sensitivity and Adherence Shape the GLP-1 Market
27.25
How Supply and Demand for Weight Loss Drugs is Playing Out in 2026
25.94
2024 was a record year for obesity trials and 2025 is already poised to take over
25.39
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
26.17
GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans
21.76
00174-1/asset/473a4568-c02a-4279-8d62-97acf54dda57/main.assets/gr2_lrg.jpg)
